ClinicalTrials.gg
Status unknownNCT02790762Updated Jun 6, 2016

Human Umbilical Cord-Mesenchymal Stem Cells for Pneumoconiosis

A Phase 1 interventional study of Human umbilical cord mesenchymal stem cells in Pneumoconiosis, sponsored by Shenzhen Hornetcorn Bio-technology Company, LTD. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-06-06.

Sponsored by Shenzhen Hornetcorn Bio-technology Company, LTD · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2016), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for Pneumoconiosis.

Read the detailed description

Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into mature cells typical of several tissues, which have been confirmed in in vivo and in vitro experiments.

To investigate the effects of hUC-MSC treatment for Pneumoconiosis, 10 patients with Pneumoconiosis will be enrolled and receive 4 times of hUC-MSC transplantation.

02

Conditions studied

  • Pneumoconiosis

Keywords

  • stem cells
  • Mesenchymal Stem Cells
  • Umbilical Cord-Mesenchymal Stem Cells
  • Pneumoconiosis
03

In context

Lead sponsor

Shenzhen Hornetcorn Bio-technology Company, LTD is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient who have signed the document;
  • Clinical and radiological evidence of liver cirrhosis.

Exclusion criteria

Exclusion Criteria:

  • Pregnant women or lactating mothers;
  • History of neurological disease, head injury or psychiatric disorder;
  • Patients with positive human immunodeficiency () at screening indicative of current of pass infection;
  • With malignant tumors;
  • Abnormal blood coagulation, combine other tumor or special condition;
  • Patients who had participated in other clinical trials within three months prior to this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    hUC-MSC treatment

    Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.

    Biological: Human umbilical cord mesenchymal stem cells

Interventions

06

What researchers measure

Primary outcomes

  1. Severity of adverse events

    According to National Cancer Institute Common Terminology Criteria for Adverse Events(NCI-CTCAE)

    Time frame: 12 months

Secondary outcomes

  1. Immunological Indicator in serum

    Expression levels of various cytokines including interferon-γ、IL-2、IL-1β、IL-4 and transforming growth factor-β1 in serum(U/ml).

    Time frame: 1, 3 ,6 and 12 months

  2. The level of ceruloplasmin in serum

    Time frame: 1, 3 ,6 and 12 months

  3. The level of type Ⅲ procollagen peptide in serum

    Time frame: 1, 3 ,6 and 12 months

  4. Lung function as assessed by spirometry

    Time frame: 1, 3 ,6 and 12 months

  5. Chest high kilovolt X-ray examination

    Time frame: 12 month

07

Study locations

1 site
  • The second Affiliated Hospital of University of Soth China
    Hengyang, Hunan 431224, China
    • Guo Q Li, Professor · ContactLiGQ@126.com · 0734-8899939
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Jun 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2016
First posted
Jun 6, 2016
Start
Jun 2016
Primary completionEst.
Jun 2017
CompletionEst.
Oct 2017
Last update
Jun 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02790762
Lead sponsor
Shenzhen Hornetcorn Bio-technology Company, LTD
Collaborators
The Second Hospital University of South China
Responsible party
Sponsor
First posted
Jun 6, 2016
Start date
Jun 2016
Primary completion
Jun 2017 (estimated)
Completion
Oct 2017 (estimated)
Last update
Jun 6, 2016

Study contacts

Jin S Cao, lab master
Contact
CaoJS@hornetcon.com
+86 0734-53137955
Guo Q Li, Professor
principal investigator · The second Affiliated Hospital of University of Soth China

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion